Amiodarone reduces ventricular arrhythmias in advanced heart failure but may increase mortality, while catheter ablation and mechanical support offer effective management options.
How should ventricular arrhythmias be managed in patients with advanced heart failure?
This review highlights that while amiodarone and catheter ablation can suppress ventricular arrhythmias in advanced heart failure, high-risk patients may require mechanical circulatory support or heart transplantation.
Advanced heart failure (A-HF) is characterized by progressive symptoms of heart failure despite optimal therapy. In patients with A-HF, ventricular arrhythmias (VAs) are common. Clinical studies evaluating different therapies to prevent VAs had very limited representation of patients with A-HF. Among antiarrhythmic drugs, only amiodarone reduces VAs, although its use may be associated with increased mortality. Catheter ablation with substrate modification is effective to achieve VA suppression in patients with A-HF, including those with left ventricular assist devices. In high-risk cases, temporary mechanical hemodynamic support tailored to the individual patient on the basis of presentation and hemodynamic conditions may be beneficial. Advanced therapies for pump failure or refractory VAs, including heart transplantation and durable mechanical circulatory support, may be required in high-risk patients who are reasonable candidates for these surgical therapies. In this review, the authors discuss important management considerations in patients with VAs and A-HF.
“We thought that supporting patients with a high-flow device would improve outcomes in terms of 30-day and one-year mortality, since prior reports suggested it would. Yet we found it had no significant impact. Numerically, there was a significant reduction in periprocedural acute hemodynamic decompensation events in the device arm, but this benefit was offset by a tenfold higher rate of complications with the Impella device.”
Santangeli et al. (Sat,) conducted a review in Advanced heart failure with ventricular arrhythmias. Management strategies (amiodarone, catheter ablation, mechanical support) was evaluated. Amiodarone reduces ventricular arrhythmias in advanced heart failure but may increase mortality, while catheter ablation and mechanical support offer effective management options.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: